Literature DB >> 7884670

A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate.

F Bressolle1, R Gomeni, R Alric, M J Royer-Morrot, J Necciari.   

Abstract

The pharmacokinetics of valproic acid after oral administration of sustained-release formulations were studied in 12 healthy volunteers. The objective of the present study was to find an appropriate mathematical model to describe the complex drug intake process. The concentration of valproic acid in plasma was measured by HPLC. For each subject, during the input process a double peak phenomenon was observed, the plasma concentrations were fitted according to a single or a double Weibull input function, and then a first-order elimination rate was used to describe the observed data. The Weibull model was considered as an approximation of the overall process. The mean peak plasma concentration, 34.6 +/- 8.9 mg/L, was reached after 8.6 +/- 2.7 h. A single Weibull function adequately described the observed data for three subjects; the mean Weibull parameters were td (the time necessary to transfer 63% of the administered drug into the systemic circulation) of 7.87 +/- 3.53 h and gamma (shape) of 1.16 +/- 0.66. A double Weibull input function was used for nine subjects; the mean Weibull parameters were td1 = 2.35 +/- 1.18 h and td2 = 9.36 +/- 4.47 h and gamma 1 = 1.77 +/- 2.27 and gamma 2 = 3.68 +/- 3.26. The mean half-life value of the elimination phase was 14.4 +/- 4.6 h.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884670     DOI: 10.1002/jps.2600831019

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.

Authors:  Elena Soto; Sebastian Haertter; Michael Koenen-Bergmann; Alexander Staab; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2009-12-29       Impact factor: 4.200

3.  Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.

Authors:  Hee-Doo Yoo; Mi-Suk Kim; Hea-Young Cho; Yong-Bok Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-04-08       Impact factor: 2.953

4.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

5.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

6.  Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.

Authors:  Itay Perlstein; Avia Merenlender Wagner; Roberto Gomeni; Michael Lamson; Eran Harary; Ofer Spiegelstein; Attila Kalmanczhelyi; Ryan Tiver; Pippa Loupe; Micha Levi; Anna Elgart
Journal:  Clin Pharmacol Drug Dev       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.